Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); it does not constitute any investment advice.
On August 30, 2024, according to the announcement on the CDE official website, the IND application for "KQ-2002 CAR-T Cell Injection" submitted by Novatim Immune Therapeutics (Zhejiang) Co., Ltd. ("Novatim") has been accepted. Public information shows that KQ-2002 CAR-T Cell Injection is a CD19&CD22 enhanced dual-target autologous CAR-T product independently developed by Novatim, intended for the treatment of high-grade B-cell lymphoma.
KQ-2002 CAR-T Cell Injection is developed based on Novatim's independently innovated and enhanced dual-target CAR-T technology platform — the K2 CAR-T platform. This technology overcomes the key challenges of traditional CAR-T therapies, such as the high recurrence rate in treating blood tumors and weak efficacy in solid tumors. The limited migration of CAR-T cells to tumor sites and low CAR-T expansion levels are critical factors affecting CAR-T efficacy. K2 CAR-T enhances treatment outcomes through three technological innovations:
Image Source: Novatim Official Website In addition, based on the K2 CAR-T technology, Novatim has independently developed three leading enhanced dual-target CAR-T pipelines: KQ-2003 (BCMA & CD19), KQ-2206 (CD70 dual epitopes), and RD27 (BCMA & GPRC5D).
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. was established in 2018 as a biopharmaceutical technology enterprise focused on the research and development and clinical application of innovative drugs for cancer immunotherapy. It wholly owns Shanghai Novatim Pharmaceuticals Technology Co., Ltd. Based on clinical needs, the company is committed to developing first-in-class and best-in-class drugs through efficient and groundbreaking R&D innovation. Focusing on key technology development in cancer immunotherapy, the company has built three major R&D platforms: a bifunctional antibody platform, a nano bispecific ADC platform, and an enhanced dual-target CAR-T platform. Through hierarchical breakthroughs in key technologies, the company is developing approximately 10 FIC/BIC products.The company independently developed the world's first therapy specifically targeting rrMM (with extramedullary involvement) andPOEMS SyndromeCAR-T, currently in clinical PhaseⅠ/Ⅱa.
